GeneBioTech Ltd Past Earnings Performance
Past criteria checks 5/6
GeneBioTech has been growing earnings at an average annual rate of 22.4%, while the Biotechs industry saw earnings growing at 14.4% annually. Revenues have been growing at an average rate of 8.7% per year. GeneBioTech's return on equity is 5.3%, and it has net margins of 3.2%.
Key information
22.4%
Earnings growth rate
22.4%
EPS growth rate
Biotechs Industry Growth | 11.7% |
Revenue growth rate | 8.7% |
Return on equity | 5.3% |
Net Margin | 3.2% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Market Cool On GeneBioTech Co. ,Ltd's (KOSDAQ:086060) Earnings
Aug 12We Like The Quality Of GeneBioTech Ltd's (KOSDAQ:086060) Earnings
Mar 22Read This Before Buying GeneBioTech Co. ,Ltd (KOSDAQ:086060) For Its Dividend
Apr 15Should GeneBioTech Ltd (KOSDAQ:086060) Be Disappointed With Their 90% Profit?
Mar 18Here's Why Genebiotech (KOSDAQ:086060) Has A Meaningful Debt Burden
Feb 17How Does Genebiotech Co., Ltd. (KOSDAQ:086060) Fare As A Dividend Stock?
Jan 10Is Genebiotech (KOSDAQ:086060) A Risky Investment?
Nov 19Revenue & Expenses Breakdown
How GeneBioTech Ltd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 80,266 | 2,605 | 8,371 | 860 |
31 Dec 23 | 79,477 | 2,591 | 8,427 | 837 |
30 Sep 23 | 82,466 | 3,594 | 8,281 | 959 |
30 Jun 23 | 84,897 | 2,600 | 7,930 | 959 |
31 Mar 23 | 83,007 | 1,847 | 7,704 | 959 |
31 Dec 22 | 82,759 | 1,523 | 7,647 | 765 |
30 Sep 22 | 78,270 | 316 | 8,279 | 213 |
30 Jun 22 | 71,338 | 415 | 7,686 | 413 |
31 Mar 22 | 68,923 | 338 | 7,245 | 621 |
31 Dec 21 | 62,814 | -484 | 6,749 | 821 |
30 Sep 21 | 55,601 | -486 | 8,982 | 820 |
30 Jun 21 | 56,974 | 189 | 8,841 | 883 |
31 Mar 21 | 58,137 | 103 | 9,301 | 986 |
31 Dec 20 | 59,119 | 1,029 | 9,237 | 1,033 |
30 Sep 20 | 62,309 | 905 | 7,613 | 1,070 |
30 Jun 20 | 59,849 | 493 | 7,670 | 1,040 |
31 Mar 20 | 58,482 | 1,042 | 7,189 | 1,075 |
31 Dec 19 | 58,245 | 847 | 7,401 | 1,113 |
30 Sep 19 | 59,572 | 797 | 7,075 | 1,174 |
30 Jun 19 | 59,637 | 1,386 | 7,352 | 1,222 |
31 Mar 19 | 60,224 | 2,378 | 7,163 | 1,093 |
31 Dec 18 | 62,809 | 2,683 | 6,987 | 1,052 |
30 Sep 18 | 60,961 | 1,702 | 6,728 | 990 |
30 Jun 18 | 60,652 | 1,838 | 6,341 | 963 |
31 Mar 18 | 58,785 | 2,309 | 6,373 | 1,015 |
31 Dec 17 | 55,534 | 2,089 | 6,115 | 964 |
30 Sep 17 | 56,241 | 3,934 | 5,822 | 973 |
30 Jun 17 | 56,099 | 3,429 | 5,974 | 967 |
31 Mar 17 | 55,262 | 2,402 | 5,947 | 921 |
31 Dec 16 | 55,632 | 2,734 | 5,915 | 941 |
30 Sep 16 | 54,845 | 2,163 | 5,775 | 965 |
30 Jun 16 | 55,280 | 2,393 | 5,748 | 972 |
31 Mar 16 | 54,410 | 2,235 | 5,486 | 953 |
31 Dec 15 | 52,256 | 1,712 | 5,411 | 986 |
30 Sep 15 | 51,990 | 1,635 | 5,229 | 927 |
30 Jun 15 | 51,126 | 1,404 | 5,024 | 939 |
31 Mar 15 | 50,972 | 1,312 | 5,033 | 947 |
31 Dec 14 | 51,589 | 1,091 | 5,195 | 1,104 |
30 Sep 14 | 50,192 | 1,068 | 5,236 | 1,119 |
30 Jun 14 | 51,285 | 704 | 5,356 | 1,128 |
31 Mar 14 | 52,612 | 151 | 5,539 | 1,197 |
31 Dec 13 | 55,037 | 204 | 5,315 | 1,102 |
30 Sep 13 | 56,678 | -474 | 5,393 | 1,213 |
Quality Earnings: A086060 has high quality earnings.
Growing Profit Margin: A086060's current net profit margins (3.2%) are higher than last year (2.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A086060's earnings have grown significantly by 22.4% per year over the past 5 years.
Accelerating Growth: A086060's earnings growth over the past year (41.1%) exceeds its 5-year average (22.4% per year).
Earnings vs Industry: A086060 earnings growth over the past year (41.1%) exceeded the Biotechs industry 13.4%.
Return on Equity
High ROE: A086060's Return on Equity (5.3%) is considered low.